Yeomans Consulting Group, Inc. Verona Pharma PLC Transaction History
Yeomans Consulting Group, Inc.
- $242 Billion
- Q2 2025
A detailed history of Yeomans Consulting Group, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Yeomans Consulting Group, Inc. holds 3,287 shares of VRNA stock, worth $345,726. This represents 0.12% of its overall portfolio holdings.
Number of Shares
3,287
Previous 3,802
13.55%
Holding current value
$345,726
Previous $241 Million
23.21%
% of portfolio
0.12%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding VRNA
# of Institutions
298Shares Held
73.5MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$690 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$580 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$413 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$364 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$304 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.41B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...